NCT Number: NCT00000601
Postmenopausal Hormone Therapy in Unstable Angina
To determine if estrogen therapy in postmenopausal women with unstable angina reduces the incidence of ischemic episodes.
Looking for future studies?
Notify MeKey information
Conditions
Age range
45 year–75 year
Sex eligibility
Female
Study type
Interventional
Phase
Phase 3
About this study
BACKGROUND:
Unstable angina is a frequent diagnosis in post-menopausal women and is associated with a significant risk of myocardial infarction and need for revascularization. The pathogenesis of unstable angina involves vasoconstriction superimposed on fixed disease, causing a temporary decrease in coronary blood flow. Recent catheterization studies in patients with atherosclerosis utilizing quantitative angiography and intracoronary doppler measurements of blood flow velocity suggest that endothelial dysfunction results in a paradoxical coronary vasoconstriction response to certain neurohumoral stimuli including acetylcholine, catecholamines, and serotonin with resultant myocardial ischemia. Therapeutic agents which prevent or limit this vasoconstriction may prevent recurrent ischemia and/or myocardial infarction in unstable angina patients. Recently, estrogen receptors were identified in the smooth muscle of post-mortem human coronary arteries. Work in animal models and studies in post-menopausal women suggest that intravenous estrogen acutely decreases coronary vascular resistance, increases coronary blood flow, and prevents the paradoxical response to acetylcholine in patients with endothelial dysfunction.
DESIGN NARRATIVE:
The randomized, double-blind, placebo-controlled, multi-center trial tested the hypothesis that intravenous estrogen followed by oral estrogen and the combination of intravenous and oral estrogen and progesterone in the routine management of unstable angina were beneficial compared with placebo in post-menopausal women. Subjects with rest angina and no contraindications to hormone therapy were randomized to receive intravenous followed by oral conjugated estrogen for 21 days, intravenous estrogen followed by oral conjugated estrogen plus medroxyprogesterone for 21 days or placebo. The primary end point was the number of ambulatory electrocardiographic ischemic events over the first 48 hours. Clinical events were also determined over six months of follow-up.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Postmenopausal women with unstable angina.
Treatment and study plan
estrogens
DrugProgesterone
Drughormone replacement therapy
DrugSponsors and collaborators
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Nih
Registry information
Important dates
- Study start
- 1995
- Study completion
- 2000
- First posted
- Oct 28, 1999
- Registry last updated
- Feb 18, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Multicenter Study of Silent Myocardial Ischemia (MSSMI)
NCT00005216
Angina Pectoris, Angina, Unstable
View Trial DetailsIMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
NCT00091507
Acute Coronary Syndrome, Angina Pectoris
Anchorage, Alaska, United States
View Trial DetailsUnstable Angina Pectoris Trial
NCT00000486
Angina Pectoris, Angina, Unstable
View Trial DetailsMersey Acute Coronary Syndrome Rule-Out Using High Sensitive Troponin
NCT02581540
Acute Coronary Syndrome, Angina Pectoris
View Trial Details